Anglaret X et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d'Ivoire: a randomised trial. Lancet 353: 1463-1468, 1999.

Antinori A et al. Failure of low-dose dapsone-pyrimethamine in primary prophylaxis of Pneumocystis carinii pneumonia (letter). Lancet 340: 788, 1992.

Berman SA et al. Disseminated Pneumocystis carinii in a patient receiving aerosolised pentamidine prophylaxis. Western Journal of Med 153: 82-86, July l990.

Blum RN et al. Comparative trial of dapsone versus trimethoprim/sulfamethoxazole for primary prophylaxis of Pneumocystis carinii pneumonia. Journal of Acquired Immune Deficiency Sydromes 5: 341-347, 1992.

Bozzette SA et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. New England Journal of Medicine 323: 1451-1457, l990.

Bozzette SA et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. New England Journal of Medicine 332(11): 693-699, 1995.

Buskin SE et al. Heavy smoking increases the risk of Pneumocystis carinii pneumonia (PCP). Eighth International Conference on AIDS, Amsterdam, abstract WeC 1030, 1992.

Castellano AR et al. Cost and benefit of secondary prophylaxis for Pneumocystis carinii pneumonia. Journal of the American Medical Association 266(6): 820-824, 1991.

Caumes E et al. Effect of corticosteroids on the incidence of adverse cutaneous reactions to trimethoprim-sulfamethoxazole during treatment of AIDS-associated Pneumocystis carinii pneumonia. Clinical Infectious Diseases 18: 319-323, 1994.

Centers for Disease Control (CDC). Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with HIV. Morbidity and Mortality Weekly Report 41: 1-12, 1992.

Centers for Disease Control and Prevention (CDC). Revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. Morbidity and Mortality Weekly Report 44(RR-4): 1-12, 1995.

Chan C et al. Atovaquone suspension compared with aerosolized pentamidine for prevention of pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides. Journal of Infectious Diseases 180: 369-376, 1999.

Cheung T et al. Intramuscular pentamidine for the prevention of Pneumocystis carinii pneumonia in patients infected with human immunodeficiency virus. Clinical Infectious Diseases 16(1): 22-25, 1993.

Clement M et al. Corticosteroids as adjunctive therapy in severe Pneumocystis carinii pneumonia: a prospective placebo controlled trial. American Review of Respiratory Diseases 139:A250, 1989.

Connor E et al. Clinical and laboratory correlates of Pneumocystis carinii pneumonia in children infected with HIV. Journal of the American Medical Association 265: 1693-1697, 1991.

Dohn MN et al. Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS. Annals of Internal Medicine 121(3): 174-180, 1994.

Dore GJ et al. Impact of highly active antiretroviral therapy on individual AIDS-defining illness incidence and survival in Australia. Journal of Acquired Immune Deficiency Syndromes 29(4): 388-395, 2002.

Dunne MW et al. Efficacy of azithromycin in prevention of Pneumocystis carinii pneumonia: a randomised trial. California Collaborative Treatment Group. Lancet 354(9182): 891-895, 1999.

Dworkin MS et al. Risk for primary Pneumocystis carinii pneumonia after the CD4+ T-lymphocyte count rises above 200 cells/ul. 36th Annual Meeting of the Infectious Diseases Society of America, abstract 7, Denver, 1998.

Dworkin M et al for the HIV Disease Project. Prophylaxis with trimethoprim-sulfamethoxazole for human immunodeficiency virus-infected patients: impact on risk for infectious diseases. Clinical Infectious Diseases 33(3): 393-398, 2001.

El-Sadr W et al. Atovaquone compared with dapsone in the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulphonamides, or both. New England Journal of Medicine 339(26): 1889-1895, 1998.

El-Sadr W et al. A randomized trial of daily and thrice-weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected persons. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Clinical Infectious Diseases 29(4): 775-783, 1999.

European Collaborative Study Group. CD4 T cell count as predictor of Pneumocystis carinii pneumonia in children born to mothers infected with HIV. British Medical Journal 308: 437-440, 1994.

Feinberg J et al. Trimetrexate (TMTX) salvage therapy for PCP in AIDS patients with limited therapeutic options. Eighth International Conference on AIDS, Amsterdam, abstract PoB 3297, 1992.

Fischl MA et al. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. Journal of the American Medical Association 259: 1185-1189, 1988.

Freedberg KA et al. Primary prophylaxis for Pneumocystis carinii pneumonia in HIV-infected people with CD4 counts below 200/mm³: A cost-effectiveness analysis. Journal of Acquired Immune Deficiency Syndromes 4: 521-531, 1991.

Furrer H et al. Discontinuation of primary prophylaxis against pneumoncystic carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. New England Journal of Medicine 340(17): 1301-1306, 1999.

Furrer H et al. Discontinuation of primary prophylaxis in HIV-infected patients at high risk of Pneumocystis carinii pneumonia: prospective multicentre study. AIDS 15(4): 501-507, 2001.

Gagnon S et al. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome - a double-blind, placebo-controlled trial. New England Journal of Medicine 323: 1444-1450, l990.

Giesser IL et al. An epidemiological study of HIV-infections in Frankfurt/Main and other major cities in Germany. International Journal of Hygiene and Environmental Health 203(5-6): 393-399, 2001.

Girard PM. Discontinuing Pneumocystic carinii pneumonia - Editorial. New England Journal of Medicine 344(3): 222-223, 2001.

Girard PM et al. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. New England Journal of Medicine 328: 1514-1520, 1993.

Hand IL et al. Aerosolized pentamidine for prophylaxis of Pneumocystis carinii pneumonia in infants with human immunodeficiency virus infection. Pediatric Infectious Diseases Journal 13: 100-104, 1994.

Hardy et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome (ACTG 021). New England Journal of Medicine 327(26): 1842-1848, 1992.

Helweg-Larsen J et al. Effects of mutations in Pneumoncystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P carinii pneumonia. Lancet 354(9187): 1347-1351, 1999.

Hirschel B et al. A controlled study of inhaled pentamidine for primary prevention of PCP. New England Journal of Medicine 324: 1087-1093, 1991.

Horowitz HW et al. Atovaquone compared with dapsone to prevent pneumocystis carinii pneumonia. New Englang Journal of Medicine 340(19): 1512-1513.

Hughes W. A new drug (566C80) for the treatment of Pneumocystis carinii pneumonia. Annals of Internal Medicine 116(11): 953-954, 1992.

Hughes WT et al. Comparison of 566C80 and trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. New England Journal of Medicine 328: 1521-1527, 1993.

Jensen AM et al. Does cytomegalovirus predict a poor prognosis in Pneumocystis carinii pneumonia treated with corticosteroids? A note for caution. Chest 108(2): 411-414, 1995.

Jourdain G et al. Trimethoprim-sulfamethoxazole for Pneumocystis carinii pneumonia (PCP) prophylaxis during pregancy in Thailand: safety and efficacy data. Thirteenth International AIDS Conference, Durban, abstract B3137, 2000.

Kamarulzaman A et al. Clinical spectrum of opportunistic disease and survival in HIV-infected patients in Kuala Lumpur, Malaysia. Antiviral Therapy 8 (Suppl. 1): abstract 1201. 2003.

Kancheya N et al. Incidence and predictors of severe bacterial infections in HIV-infected Zambian men and women. Antiviral Therapy 8 (Suppl. 1): abstract 912. 2003.

Kazanjian P et al. Pneumocystis carinii cytochrome b mutations are associated with atovaquone exposure in patients with AIDS. Journal of Infectious Diseases 183(5): 819-822, 2001.

Kazanjian P et al. Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients. Journal of Infectious Diseases 182(2): 551-557, 2000.

Keating J et al. Double blind controlled trial of corticosteroid therapy in mild Pneumocystis carinii pneumonia (PCP) in AIDS patients. Fourth European Conference on Clinical Aspects and Treatment of HIV Infection, Milan, abstract O29, 1994.

Keiser P et al. Prednisone therapy is not associated with increased risk of herpetic infections in patients infected with human immunodeficiency virus. Clinical Infectious Diseases 23(1): 201-202, 1996.

Kirk O et al. Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy. AIDS 13(13): 1647-1651, 1999.

Klein N et al. Trimethoprim-sulfamethoxazole versus pentamidine for Pneumocystis carinii pneumonia in AIDS patients: results of a large prospective randomised treatment trial. AIDS 6(3): 301-305, 1992.

Koenig S et al. Presenting diagnosis among HIV-infected patients in two health centres in rural Haiti. Antiviral Therapy 8 (Suppl. 1): abstract 1125. 2003.

Koletar SL et al. A prospective study of discontinuing primary and secondary Pneumocystis carinii pneumonia prophylaxis after CD4 cell count increase to > 200 x 10⁶/l. AIDS 15(12): 1509-1515, 2001.

Kovacs J et al. Are corticosteroids beneficial as adjunctive therapy for Pneumocystis pneumonia in AIDS (editorial). Annals of Internal Medicine 113(1): 1-3, 1990.

Kovacs JA et al. CD4 T-lymphocyte counts and Pneumocystis carinii pneumonia in pediatric HIV infection. Journal of the American Medical Association 265: 1698-1703, 1991.

Kovacs JA et al. PCP prophylaxis in paediatric HIV infection: time for a change? Lancet 344: 5-6, 1994.

Kovacs JA et al. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. Journal of the American Medical Association 286(19): 2450-2460, 2001.

Koval CE et al. Immune reconstitution syndrome after successful treatment of Pneumocystis carinii pneumonia in a man with human immunodeficiency virus type 1 infection. Clinical Infectious Diseases 35(4): 491-493, 2002.

Larsen HH et al. Development of a rapid real-time PCR assay for quantitation of Pneumocystis carinii f. sp. carinii. Journal of Clinical Microbiology 40(8): 2989-93, 2002.

Ledergerber B et al. Discontinuation of secondary prophylaxis against Pneumocystic carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. New England Journal of Medicine 344(3): 168-174, 2001.

Leoung GS et al. Aerosolised pentamidine for prophylaxis against Pneumocystis carinii pneumonia - the San Francisco Community Prophylaxis study. New England Journal of Medicine 323(12): 769-775, 1990.

Leoung GS et al. Trimethoprim-sulfamethoxazole (TMP-SMZ) dose escalation versus direct rechallenge for Pneumocystis Carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with previous adverse reaction to TMP-SMZ. Journal of Infectious Diseases 184(8): 992-997, 2001.

Lopez Bernaldo de Quiros JC et al. A randomised tiral of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. New England Journal of Medicine 344(3): 159-167, 2001.

Losina E et al. The impact of a history of opportunistic diseases on chronic HIV mortality in HIV patients in the Ivory Coast. Antiviral Therapy 8 (Suppl. 1): abstract 948, 2003.

Ma L et al. Pneumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use. Journal of Infectious Diseases 180(6): 1969-1978, 1999.

Mallolas J et al. Primary prophylaxis for Pneumocystis carinii pneumonia: a randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimethamine. AIDS 7(1): 59-64, 1993.

Martin M et al. A comparison of the effectiveness of three regimens in the prevention of Pneumocystis carinii pneumonia in HIV-infected patients. Archives of Internal Medicine 152(3): 523-528, 1992.

Martin JN et al. Emergence of trimethoprim-sulfamethoxazole resistance in the AIDS era. Journal of Infectious Diseases 180(1): 1809-1818, 2000.

Masur H et al. Consensus statement on the use of corticosteroids as adjunctive therapy for Pneumocystis pneumonia in the acquired immunodeficiency syndrome. New England Journal of Medicine 323(21): 1500-1504, 1990.

Masur H. Prevention and treatment of Pneumocystis pneumonia. New England Journal of Medicine 327(26): 1853-1859, 1992.

Masur H and Kaplan J. Does Pneumocystis carinii prophylaxis still need to be lifelong? Editorial. New England Journal of Medicine 340(17): 1356, 1999.

McIntosh K et al. Toxicity and efficacy of daily vs. weekly dapsone for prevention of Pneumocyctis carinii pneumonia in children infected with HIV. Pediatric Infectious Diseases Journal 18(5): 432-439, 1999.

Medina I et al. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. New England Journal of Medicine 323: 776-782, 1990.

Mei Q et al. Failure of co-trimoxazole in Pneumocystis carinii infections and mutations in dihydropteroate synthase gene. Lancet 351(9116): 1631-1632, 2001.

Montaner J et al. Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and acquired immunodeficiency syndrome. Annals of Internal Medicine 113(1): 14-20, 1990.

Montaner JSG et al. Aerosol pentamidine for secondary prophylaxis of AIDS-related PCP. A randomised, placebo-controlled study. Annals of Internal Medicine 114: 948-953, 1991.

Montgomery AB et al. Pentamidine aerosol versus trimethoprim-sulfamethoxazole for acute Pneumocystis carinii in acquired immune deficiency syndrome. American Journal of Respiratory and Critical Care Medicine 151: 1068-1074, 1995.

Montgomery AB. Pneumocystis carinii pneumonia prophylaxis: past, present and future. AIDS 6(2): 227-228, 1992.

Murphy RL et al. Aerosol pentamidine prophylaxis following PCP in AIDS patients: results of a blinded dose-comparison study using an ultrasonic nebuliser. American Journal of Medicine 90: 418-426, 1991.

Mussini C et al. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study. Journal of Infectious Diseases 181(5): 1635-1642, 2000.

Navin TR et al. Risk factors for community acquired pneumonia among persons infected with human immunodeficiency virus. Journal of Infectious Diseases 181(1): 158-164, 2000.

Nelson MR et al. Treatment with corticosteroids - a risk factor for the development of clinical cytomegalovirus disease in AIDS. AIDS 7(3): 375-378, 1993.

Nieman RB et al. The effect of cigarette smoking on the development of AIDS in HIV-1-seropositive individuals. AIDS 7: 705-710, 1993.

Opravil M et al. Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. Clinical Infectious Diseases 20(3): 531-541, 1995.

Para MF et al. Reduced toxicity with gradual initiation of trimethoprim-sulfamethoxazole as primary prophylaxis for Pneumocystis carinii pneumonia: AIDS Clinical Trials Group 268. Journal of Acquired Immune Deficiency Syndromes 24(4): 337-343, 2000.

Petty BG et al. Escalating multiple-dose safety and tolerance study of oral WR 6026 in HIV-infected subjects: AIDS clinical trials group 173. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology 21(1): 26-31, 1999.

Podzamczer D et al. Thrice weekly co-trimoxazole is better than weekly dapsone-pyrimethamine for the prevention of Pneumocystis carinii pneumonia in HIV-infected patients. AIDS 7(4): 501-506, 1993.

Rizzardi GP et al. Better efficacy of twice-monthly than monthly aerosolised pentamidine for secondary prophylaxis of PCP in patients with AIDS. Journal of Infection 31(2): 99-105, 1995.

Rizzardi GP et al. Risks and benefits of aerosolized pentamidine and cotrimoxazole in primary prophylaxis of Pneumocystis carinii pneumonia in HIV-1-infected patients: a two-year Italian multicentric randomized controlled trial. The Italian PCP Study Group. Journal of Infection 32(2): 123-131, 1996.

Ruskin J et a. Low-dose co-trimoxazole for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus disease. Lancet 337: 468-471, 1991.

Saah AJ et al. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. Journal of the American Medical Association 273: 1197-1202, 1995.

Safrin S et al. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. Annals of Internal Medicine 124(9): 792-802, 1996.

Sahai J et al. Eflornithine for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: a preliminary review. Pharmacotherapy 9(1): 29-33, 1989.

Salmon-Ceron D et al. Lower survival in AIDS patients receiving dapsone compared with aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia. Journal of Infectious Diseases 172: 656-664, 1995.

Sattler FR et al. Trimethoprim-sulfamethoxazole compared with pentamidine for the treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Annals of Internal Medicine 109: 280-287, 1988.

Sattler FR et al. Trimetrexate with leucovorin versus trimethoprim-sulfamethoxazole for moderate to severe episodes of Pneumocystis carinii pneumonia in patients with AIDS: a prospective, controlled multicenter investigation of the AIDS Clinical Trials Group Protocol 029/031. Journal of Infectious Diseases 170(1): 165-72, 1994.

Schneider MME et al. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. New England Journal of Medicine 327: 1836-1841, 1992.

Schneider MME et al. Discontinuation of prophylaxis for pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy. Lancet 353: 201-203, 1999.

Schurmann M et al. Effectiveness of twice-weekly pyrimethamine-sulfadoxine as primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis in patients with advanced HIV infection. European Journal of Clinical Microbiology and Infectious Diseases 21(5): 353-361, 2002.

Sepkowitz KA et al. Pneumothorax in AIDS. Annals of Internal Medicine 114: 455-459, 1991.

Simonds RJ et al. The impact of prophylaxis guidelines on Pneumocystis carinii pneumonia (PCP) in infants, USA. Tenth International Conference on AIDS, Yokohama, abstract 389B, 1994.

Slavin M et al. Oral dapsone versus nebulized pentamidine for Pneumocystis carinii pneumonia prophylaxis: an open randomized prospective trial to assess efficacy and hematological toxicity. AIDS 6: 1169-1174, 1992.

Soo Hoo GW et al. Inhaled or intravenous pentamidine therapy for Pneumocystis carinii pneumonia in AIDS. Annals of Internal Medicine 113(3): 195-202, 1990.

Stein et al. Use of low-dose trimethoprim/sulfamethoxazole thrice weekly for primary and secondary prophylaxis of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients. Antimicrobial Agents & Chemotherapy 35(9): 1705-1709, 1991.

Toma E et al. Clindamycin with primaquine vs. trimethoprim-sulfamethoxazole therapy for mild and moderately severe pneumocystis carinii pneumonia in patients with AIDS: a multicentre, double-blind, randomised trial (CTN 004). Clinical Infectious Disease 27(3): 524-530, 1998.

USA Working Group on PCP Prophylaxis in Children. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with human immunodeficiency virus. Morbidity and Mortality Weekly Report 40(RR-2): 1-13, 1991.

Valentine F et al. The occurrence of opportunistic infections (OIs) at relatively high CD4 levels is associated with an antigen-specific absence of lymphocyte proliferative responses (LPR). Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, abstract 580, 2000.

Waskin H et al. Diabetes mellitus in HIV+ patients post-Pneumocystis pneumonia and the impact of aerosolised pentamidine. Sixth International Conference on AIDS, San Francisco, abstract ThB 422, 1990.

Weverling GJ et al. Discontinuation of pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. Lancet 353: 1293-1298, 1999.

Wewers MD et al. Cigarette smoking in HIV infection induces a suppressive inflammatory environment in the lung. American Journal of Respiratory and Critical Care Medicine 158(5): 1543-1549, 1998.

Wiktor SZ et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial. Lancet 353(9163): 1469-1475, 1999.

Wininger DA et al. Impact of trimethoprim-sulfamethoxazole prophylaxis on etiology and susceptibilities of pathogens causing human immunodeficiency virus-associated bacteremia. Antimicrobial Agents and Chemotherapy 46(2): 594-597, 2002.

Yangco BG et al. Discontinuation of chemoprophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection. Annals of Internal Medicine 132(3): 201-205, 2000.

Zellweger C et al. Long-term safety of discontinuation of secondary prophylaxis against Pneumocystis pneumonia: prospective multicentre study. AIDS 18: 2047-2053, 2004.